NCT03831828

Brief Summary

The incidence of esophageal squamous cell carcinoma is highly regional and familial. The current treatment plan is based on the stage and location of the tumor.By studying the relationship between the status of different genes and prognosis, it can help doctors to develop precise and individualized treatment plans.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
46

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2018

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 26, 2018

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

February 4, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 6, 2019

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2019

Completed
Last Updated

February 8, 2019

Status Verified

September 1, 2018

Enrollment Period

3 months

First QC Date

February 4, 2019

Last Update Submit

February 6, 2019

Conditions

Prognosis of Patients With ESCC

Outcome Measures

Primary Outcomes (1)

  • Gene test

    466 Tumor-associated gene test by next-generation sequencing(NGS)

    2019-2 to 2019-4

Study Arms (2)

Lymph node metastasis Positive

good prognosis; without Lymph node metastasis.

Lymph node metastasis Negative

poor prognosis; with Lymph node metastasis.

Eligibility Criteria

Age30 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Taihang Mountain area population in northern China.

You may qualify if:

  • Esophageal cancer patients who underwent surgery treatment, and postoperative pathological diagnosis was squamous cell carcinoma. Patients with ESCC have complete clinical information.

You may not qualify if:

  • Patients who also suffering from other tumors.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Junfeng Liu

Shijiazhuang, Hebei, 050000, China

RECRUITING

Central Study Contacts

Junfeng Liu, MD

CONTACT

1393115229613931152296@163.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Director of thoracic surgery

Study Record Dates

First Submitted

February 4, 2019

First Posted

February 6, 2019

Study Start

December 26, 2018

Primary Completion

April 1, 2019

Study Completion

April 1, 2019

Last Updated

February 8, 2019

Record last verified: 2018-09

Locations

CN(1)